VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00561925
First received: November 20, 2007
Last updated: March 7, 2014
Last verified: March 2014

November 20, 2007
March 7, 2014
November 2007
November 2011   (final data collection date for primary outcome measure)
Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population [ Time Frame: week 48 ] [ Designated as safety issue: No ]
Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL
The primary endpoint of this study is virologic response by Week 48. Virologic response is defined as VL <50 copies/mL prior to Week 48 and without subsequent virologic rebound or change of ARV therapy prior to Week 48.
Complete list of historical versions of study NCT00561925 on ClinicalTrials.gov Archive Site
  • Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population [ Time Frame: week 0 to 144 ] [ Designated as safety issue: No ]
  • Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population [ Time Frame: week 144 ] [ Designated as safety issue: No ]
    Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL
  • Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population [ Time Frame: week 0 to 144 ] [ Designated as safety issue: No ]
  • Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population [ Time Frame: baseline, week 144 ] [ Designated as safety issue: No ]
  • Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population [ Time Frame: baseline, week 144 ] [ Designated as safety issue: No ]
  • Occurrence of Rashes [ Time Frame: until last patient completed 144 weeks (up to 193 weeks) ] [ Designated as safety issue: No ]
    Frequency of patients with drug related rash events by functional grouping
  • Occurrence of Elevations in Laboratory Measurement by DAIDS Grade [ Time Frame: until last patient completed 144 weeks (up to 193 weeks) ] [ Designated as safety issue: No ]
  • Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication [ Time Frame: week 0 to 144 ] [ Designated as safety issue: No ]
  • Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities [ Time Frame: week 0 to 72 ] [ Designated as safety issue: No ]
  • Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities [ Time Frame: week 0 to 72 ] [ Designated as safety issue: No ]
  • Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events [ Time Frame: week 0 to 72 ] [ Designated as safety issue: No ]
  • Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash [ Time Frame: week 0 to 72 ] [ Designated as safety issue: No ]
  • Relative Bioavailability Trough C_pre,ss,1 [ Time Frame: week 132 ] [ Designated as safety issue: No ]
    Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation.
  • Occurrence of Hepatic Events [ Time Frame: until last patient completed 144 weeks (up to 193 weeks) ] [ Designated as safety issue: No ]
    Frequency of patients with hepatitis symptoms
Time to loss of virologic response with genotypic resistance, Virologic response by Week 48, Time to virologic response, Time to new AIDS or AIDS related progression event or death, Change from baseline in VL and CD4+ cell count at each visit.
Not Provided
Not Provided
 
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)

The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
HIV Infections
  • Drug: nevirapine IR
    200 mg BID
  • Drug: nevirapine XR
    400 mg QD
  • Experimental: nevirapine XR
    400 mg QD
    Intervention: Drug: nevirapine XR
  • Active Comparator: nevirapine IR
    200 mg BID
    Intervention: Drug: nevirapine IR
Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, Bogner J, Spencer D, Podzamczer D, Yong CL, Nguyen T, Zhang W, Drulak M, Quinson AM. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1068
Not Provided
November 2011   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Signed informed consent in accordance with Good Clinical Practice and local regulatory requirements prior to trial participation
  2. HIV-1 infected males or females >= 18 years of age with positive serology (ELISA) confirmed by Western blot
  3. No previous antiretroviral treatment
  4. Males with CD4+ counts >50 - <400 cells/ml or females with CD4+ counts >50-<250 cells/ml
  5. Adequate renal function defined as a calculated creatinine clearance (CLCr) greater than or equal to 50 mL/min according to the Cockcroft-Gault formula as follows:

    Male: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in mg/dl) = CLCr (mL/min).

    Female: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in mg/dl) x 0.85 = CLCr (mL/min).

  6. Karnofsky score >70 (see Appendix 10.4)
  7. An HIV-1 viral load of 1,000 copies/mL
  8. Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent important opportunistic infections as defined in Appendix 10.2
  9. Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system (listed in Appendix 10.3) during the study.
  10. For centers participating in the PK substudy only: Written informed consent in accordance with GCP and local legislation for participation in the PK substudy. Refusal to participate in the PK substudy is not an exclusion criterion for participation in the trial. Only study centers with previous experience and equipped in handling PK samples are eligible for participation in the substudy.

Exclusion criteria:

  1. Active drug abuse or chronic alcoholism at the investigator's discretion
  2. Active hepatitis B or C disease, defined as HBsAg-positive and HBV-DNA-positive or HCV-RNA-positive
  3. Female patients of child-bearing potential who: are pregnant at screening; are breast feeding; are planning to become pregnant; are not willing to use a barrier method of contraception, or; are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives Note: During participation in this study, females and males have to use barrier methods of contraception in addition or instead of ethinyl estradiol containing oral contraceptives.
  4. Laboratory parameters >DAIDS Grade 2
  5. ALT/AST > DAIDS Grade 1
  6. Hypersensitivity to any ingredients of the test products
  7. Previous use of Viramune® (nevirapine) or any other antiretroviral agents (does not include use of single dose NVP for the prevention of mother to child transmission)
  8. Resistance to NNRTIs or either one of the components of Truvada® (emtricitabine or tenofovir disoproxil fumarate) or lamivudine (3TC) based on HIV-1 genotypic resistance testing report obtained at screening
  9. Patients who are receiving other concomitant treatments which are not permitted, as described in the prescribing information
  10. Use of investigational medications (any experimental agent other than the study regimen) within 30 days before study entry or during the trial
  11. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2)
  12. Patients who have been diagnosed with malignant disease
  13. Patients who in the opinion of the investigator are not candidates for inclusion in the study
  14. Patient with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma
  15. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico,   Canada,   Botswana,   South Africa,   Netherlands,   Belgium,   France,   Spain,   Portugal,   Ireland,   Italy,   Romania,   Switzerland,   United Kingdom,   Poland,   Germany,   Mexico,   Argentina,   Australia,   Russian Federation
 
NCT00561925
1100.1486, 2007-003654-29
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP